Corcept TherapeuticsCORT +2.14%82 FCF Yield % is 1.37 as of Jun. 25, 2026, which is 70% below its 10-year median of 4.50. GuruFocus rates CORT with a GF Score™ of 82/100 and a GF Value™ of $61.59 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,418 Biotechnology companies, Corcept Therapeutics ranks better than 86.74% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Corcept Therapeutics FCF Yield % Related Terms
Corcept Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corcept Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (CORT) has a FCF Yield % of 1.37 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Corcept Therapeutics and its competitors. This is 70% below median its historical median of 4.50. Over the past decade, Corcept Therapeutics' FCF Yield % has ranged from 1.32 to 11.12. According to the industry distribution chart, Corcept Therapeutics ranks #188 out of 1418 companies in the Biotechnology industry, placing it in the top 13.3%.
Is Corcept Therapeutics' FCF Yield % too high?
Corcept Therapeutics' current FCF Yield % of 1.37 is 70% below median its 10-year median of 4.50. Over the past 10 years, this metric has ranged from a low of 1.32 to a high of 11.12. Based on the distribution chart, Corcept Therapeutics ranks #188 out of 1418 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' FCF Yield % compare to PCVX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #188 out of 1418 companies for FCF Yield %. This places Corcept Therapeutics in the top 13% of its industry — outperforming the majority of peers. Historically, Corcept Therapeutics' own FCF Yield % has ranged from 1.32 to 11.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current FCF Yield % is 1.37, which is 70% below median its own 10-year median of 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.59, compared to a current price of $81.56 — trading 32.4% above its estimated fair value. The current FCF Yield % is 1.37, which is 70% below median its 10-year median of 4.50. Corcept Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current FCF Yield % is 1.37 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $81.56 is trading 32.4% above its estimated GF Value™ of $61.59.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
FCF Yield %: 1.37 (70% below median its 10-year median of 4.50)
GF Value™: $61.59 vs. price of $81.56 (32.4% above fair value)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score
Get the complete analysis for CORT
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 
